"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 3 | 1 | 4 |
| 2000 | 3 | 0 | 3 |
| 2001 | 6 | 1 | 7 |
| 2002 | 1 | 2 | 3 |
| 2003 | 4 | 2 | 6 |
| 2004 | 4 | 0 | 4 |
| 2005 | 3 | 4 | 7 |
| 2006 | 0 | 3 | 3 |
| 2007 | 3 | 0 | 3 |
| 2008 | 4 | 2 | 6 |
| 2009 | 7 | 0 | 7 |
| 2010 | 2 | 3 | 5 |
| 2011 | 2 | 0 | 2 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 0 | 5 |
| 2014 | 3 | 5 | 8 |
| 2015 | 4 | 6 | 10 |
| 2016 | 3 | 11 | 14 |
| 2017 | 4 | 6 | 10 |
| 2018 | 2 | 16 | 18 |
| 2019 | 2 | 11 | 13 |
| 2020 | 6 | 4 | 10 |
| 2021 | 9 | 9 | 18 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 3 | 3 |
| 2024 | 6 | 6 | 12 |
| 2025 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenstr?m macroglobulinemia: a pooled analysis. Blood Adv. 2025 Sep 23; 9(18):4705-4715.
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 Sep 16; 135(18).
-
Personalized endpoints in Prader-Willi syndrome: a case study with goal attainment scaling. J Clin Sleep Med. 2025 Jul 01; 21(7):1305-1309.
-
Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia. PLoS One. 2025; 20(6):e0324443.
-
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenstr?m macroglobulinemia. Blood Adv. 2025 Feb 25; 9(4):722-728.
-
Zanubrutinib for the treatment of Bing-Neel syndrome. Br J Haematol. 2025 Apr; 206(4):1136-1140.
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion. Oncologist. 2025 Jan 17; 30(1).
-
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin. 2025 Mar-Apr; 75(2):141-167.
-
Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Curr Oncol. 2024 Dec 27; 32(1).